TY - JOUR
T1 - A novel blood proteomic signature for prostate cancer
AU - Muazzam, Ammara
AU - Spick, Matt
AU - Cexus, Olivier N. F.
AU - Geary, Bethany
AU - Azhar, Fowz
AU - Pandha, Hardev
AU - Michael, Agnieszka
AU - Reed, Rachel
AU - Lennon, Sarah
AU - Gethings, Lee A.
AU - Plumb, Robert S.
AU - Whetton, Anthony D.
AU - Geifman, Nophar
AU - Townsend, Paul A.
N1 - Funding Information:
Funding was provided by Punjab Educational Endowment Fund (PEEF/SSMS/17/184) to P.A.T. to support A.M. The Stoller Biomarker Discovery Centre established with an award from the Medical Research Council (MR/M008959) to A.D.W. and P.A.T and other investigators. This work was supported by the CRUK Manchester Centre award (C5759/A25254) and Bloodwise (Blood Cancer UK Award 19007) to A.D.W. A.T. is also supported by Male Uprising in Guernsey and Hope for Guernsey charities.
Copyright:
© 2023 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2023/2/7
Y1 - 2023/2/7
N2 - Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.
AB - Prostate cancer is the most common malignant tumour in men. Improved testing for diagnosis, risk prediction, and response to treatment would improve care. Here, we identified a proteomic signature of prostate cancer in peripheral blood using data-independent acquisition mass spectrometry combined with machine learning. A highly predictive signature was derived, which was associated with relevant pathways, including the coagulation, complement, and clotting cascades, as well as plasma lipoprotein particle remodeling. We further validated the identified biomarkers against a second cohort, identifying a panel of five key markers (GP5, SERPINA5, ECM1, IGHG1, and THBS1) which retained most of the diagnostic power of the overall dataset, achieving an AUC of 0.91. Taken together, this study provides a proteomic signature complementary to PSA for the diagnosis of patients with localised prostate cancer, with the further potential for assessing risk of future development of prostate cancer. Data are available via ProteomeXchange with identifier PXD025484.
KW - prostate cancer
KW - clinical onset
KW - biomarkers
KW - proteomics
KW - SWATH-MS
KW - complement cascade
UR - http://www.scopus.com/inward/record.url?scp=85149121370&partnerID=8YFLogxK
U2 - 10.3390/cancers15041051
DO - 10.3390/cancers15041051
M3 - Article
C2 - 36831393
SN - 2072-6694
VL - 15
JO - Cancers
JF - Cancers
IS - 4
M1 - 1051
ER -
